Xoma announces closing of tender offer for HilleVax

XOMA Royalty (XOMA) announced the Company has completed its previously announced tender offer to acquire all outstanding shares of HilleVax (HLVX) common stock for a price per share of $1.95 in cash, plus one non-tradeable contingent value right. The tender offer and related withdrawal rights expired one minute after 11:59 p.m. Eastern Time on Monday, September 15, 2025. As of the Expiration Date, a total of 39,214,689 shares of HilleVax common stock were validly tendered, and not validly withdrawn, representing approximately 77.48% of the outstanding shares of HilleVax common stock as of the Expiration Date. As of the Expiration Date, the number of shares validly tendered in accordance with the terms of the tender offer and not validly withdrawn satisfied the minimum tender condition, and all other conditions to the tender offer were satisfied or waived. Immediately after the Expiration Date, XOMA Royalty irrevocably accepted for payment all shares validly tendered and not validly withdrawn and expects to promptly pay for such shares. Following the closing of the tender offer, a subsidiary of the Company, XRA 4 Corp., merged with and into HilleVax, and all shares of HilleVax common stock that had not been validly tendered were converted into the right to receive the Offer Price. As a result of the Merger, HilleVax became a wholly owned subsidiary of XOMA Royalty. Prior to the opening of trading on The Nasdaq Stock Market on September 17, 2025, all shares of HilleVax common stock will cease trading on Nasdaq, and HilleVax intends promptly to cause such shares to be delisted from Nasdaq and deregistered under the Securities Exchange Act of 1934, as amended.